Literature DB >> 26150475

Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma.

Jian Jiao1, Yu Fan2, Yan Zhang3.   

Abstract

OBJECTIVE: To measure levels of microRNA (miR)-21 and its target gene, programmed cell death 4 (PDCD4), in samples of human cutaneous malignant melanoma and normal non-malignant control skin.
METHODS: Relative levels of miR-21 and PDCD4 mRNA were measured using a quantitative real-time reverse transcription-polymerase chain reaction. Correlations between the levels of the two molecules and the clinicopathological characteristics of malignant melanoma were analysed.
RESULTS: A total of 67 cases of human cutaneous malignant melanoma were analysed and compared with 67 samples of normal nonmalignant control skin. Compared with normal skin samples, the relative level of miR-21 was significantly higher and the relative level of PDCD4 mRNA was significantly lower in the melanoma specimens. A significant negative correlation between PDCD4 mRNA and miR-21 was demonstrated in malignant melanoma (r = -0.602). Elevated miR-21 and reduced PDCD4 mRNA levels were both significantly correlated with increased tumour size, a higher Clark classification level and the presence of lymph node metastases in malignant melanoma.
CONCLUSIONS: These findings suggest that miR-21 and PDCD4 might be potential biomarkers for malignant melanoma and might provide treatment targets in the future.
© The Author(s) 2015.

Entities:  

Keywords:  Malignant melanoma; microRNA-21; programmed cell death 4; real-time polymerase chain reaction

Mesh:

Substances:

Year:  2015        PMID: 26150475     DOI: 10.1177/0300060515583707

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

Review 1.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

2.  MicroRNA-139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K/AKT signaling pathway by binding to IGF1R.

Authors:  Chaoying Yang; Zhaoxia Xia; Lifei Zhu; Yanchang Li; Zhixin Zheng; Jianying Liang; Liangcai Wu
Journal:  Cell Cycle       Date:  2019-11-14       Impact factor: 4.534

3.  Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.

Authors:  Michael Olvedy; Julie C Tisserand; Flavie Luciani; Bram Boeckx; Jasper Wouters; Sophie Lopez; Florian Rambow; Sara Aibar; Bernard Thienpont; Jasmine Barra; Corinna Köhler; Enrico Radaelli; Sophie Tartare-Deckert; Stein Aerts; Patrice Dubreuil; Joost J van den Oord; Diether Lambrechts; Paulo De Sepulveda; Jean-Christophe Marine
Journal:  J Clin Invest       Date:  2017-05-02       Impact factor: 14.808

4.  Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.

Authors:  Ming Gao; Yuan Chang; Xiuyong Wang; Chao Ban; Fan Zhang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 5.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

Review 6.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 7.  New Insight into microRNA Functions in Cancer: Oncogene-microRNA-Tumor Suppressor Gene Network.

Authors:  Kecheng Zhou; Minxia Liu; Yi Cao
Journal:  Front Mol Biosci       Date:  2017-07-07

Review 8.  Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Mahdi Mohaqiq; Hamed Shoorei; Aria Baniahmad; Mohammad Taheri; Elena Jamali
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

Review 9.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

10.  Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells.

Authors:  Thuy T Tran; Chetan K Rane; Christopher R Zito; Sarah A Weiss; Shlomit Jessel; Liliana Lucca; Benjamin Y Lu; Victor O Oria; Adebowale Adeniran; Veronica L Chiang; Sacit Bulent Omay; David A Hafler; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.